Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis

摘要: Treatment-related adverse events (AE) were more frequent in older patients treated by pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C (CHC), and most of them required dose reduction. A meta-regression analysis was conducted to explore the possible reasons this occurrence. We searched MEDLINE, EMBASE, Web Science through May 2013, clinical trials examining safety PEG-IFN RBV elderly with CHC. Data extracted host, viral, outcome information. Single-arm meta-analysis performed evaluate AE. Meta-regression predictors reduction secondary Eighteen observational studies met inclusion criteria. The overall incidences AE 61.3 %. Dose reductions due 54.2 In genotype 1, rate sustained virological response (SVR) 36.9 genotypes 2 or 3, SVR 72.8 Patients have a tendency toward lower likelihood obtaining (coefficient:−0.529), especially 1 patients. Host factors (male gender, coefficient 4.403; higher body weight, 0.140; advanced fibrosis stage, 1.582) viral (HCV 2.279) significant impact on Some host affected Increasing rates age may play role as mechanism affecting different groups.